News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
655,558 Results
Type
Article (32725)
Company Profile (180)
Press Release (622707)
Multimedia
Podcasts (89)
Webinars (9)
Section
Business (211435)
Career Advice (1733)
Deals (31630)
Drug Delivery (107)
Drug Development (77552)
Employer Resources (110)
FDA (15524)
Job Trends (12347)
News (315446)
Policy (27401)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (9)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (1989)
Accelerated approval (62)
ADA (35)
Adcomms (23)
Allergies (174)
Alliances (43447)
ALS (228)
Alzheimer's disease (1712)
Antibody-drug conjugate (ADC) (568)
Approvals (16215)
Artificial intelligence (677)
ASCO (301)
Autoimmune disease (394)
Automation (55)
Bankruptcy (322)
Belgium (6)
Best Places to Work (9854)
BIO (65)
Biologics (15)
BIOSECURE Act (15)
Biosimilars (229)
BioSpace Insights (79)
Biotechnology (121)
Bispecific (2)
Bladder cancer (211)
Brain cancer (74)
Breast cancer (805)
Cancer (6417)
Cardiovascular disease (509)
Career advice (1495)
Career pathing (42)
CAR-T (357)
CDC (48)
CDMO (122)
Celiac Disease (4)
Cell-line development (1)
Cell therapy (929)
Cervical cancer (53)
Clinical research (69549)
Collaboration (2042)
Commercialization (9)
Company closure (5)
Compensation (1690)
Complete response letters (70)
COVID-19 (2236)
CRISPR (113)
C-suite (1335)
Cystic fibrosis (149)
Data (8905)
Decentralized trials (1)
Denatured (10)
Depression (184)
Dermatology (120)
Diabetes (624)
Diagnostics (6114)
Digital health (53)
Diversity (6)
Diversity, equity & inclusion (31)
Drug discovery (335)
Drug pricing (133)
Drug shortages (14)
Duchenne muscular dystrophy (300)
Earnings (90169)
Editorial (59)
Employer branding (11)
Employer resources (105)
Events (107918)
Executive appointments (1112)
Eye disease (1)
FDA (19842)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (22)
Frontotemporal dementia (37)
Funding (1772)
Gene editing (241)
Generative AI (51)
Gene therapy (737)
GLP-1 (925)
Government (3300)
Grass and pollen (6)
Guidances (401)
Healthcare (15551)
Hematology (177)
HIV (92)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (127)
Immunology and inflammation (301)
Immuno-oncology (121)
Indications (239)
Infectious disease (2580)
Inflammatory bowel disease (220)
Inflation Reduction Act (13)
Influenza (131)
Intellectual property (320)
Interviews (324)
IPO (15137)
IRA (42)
Job creations (2834)
Job search strategy (1195)
JPM (42)
Kidney cancer (23)
Kidney disease (81)
Labor market (82)
Layoffs (439)
Leadership (43)
Legal (6583)
Licensing (32)
Liver cancer (99)
Longevity (33)
Lung cancer (911)
Lymphoma (481)
Machine learning (51)
Management (40)
Manufacturing (1050)
Marketing (11)
MASH (205)
Medical affairs (3)
Medical device (12264)
Medtech (12481)
Mergers & acquisitions (17764)
Metabolic disorders (1512)
mRNA (215)
Multiple sclerosis (192)
Multispecific (1)
NASH (20)
Netherlands (4)
Neurodegenerative disease (484)
Neuropsychiatric disorders (106)
Neuroscience (3376)
Neurotech (1)
NextGen: Class of 2026 (5128)
Non-profit (2799)
Now hiring (20)
Obesity (652)
Opinion (253)
Ovarian cancer (238)
Pain (281)
Pancreatic cancer (374)
Parkinson's disease (390)
Partnered (30)
Patents (653)
Patient advocacy (1)
Patient recruitment (940)
Patient selection (13)
Peanut (58)
People (52725)
Peptides (7)
Pharmaceutical (39)
Pharmacy benefit managers (16)
Phase 1 (22218)
Phase 2 (30441)
Phase 3 (22540)
Pipeline (11370)
Policy (238)
Postmarket research (2322)
Preclinical (8813)
Press Release (57)
Prostate cancer (326)
Psychedelics (59)
Radiopharmaceuticals (330)
Rare diseases (1222)
Real estate (4606)
Recruiting (50)
Regenerative medicine (5)
Regulatory (23483)
Reports (44)
Research institute (1826)
Resumes & cover letters (298)
Rett syndrome (49)
RNA editing (22)
RSV (84)
Schizophrenia (184)
Series A (313)
Series B (231)
Service/supplier (7)
Sickle cell disease (122)
Special edition (27)
Spinal muscular atrophy (179)
Sponsored (38)
Startups (3173)
Stomach cancer (20)
Substance use disorders (18)
Supply chain (99)
Tariffs (63)
The Weekly (78)
Vaccines (1013)
Venture capital (103)
Weight loss (388)
Women's health (137)
Worklife (15)
Date
Today (123)
Last 7 days (494)
Last 30 days (2171)
Last 365 days (27855)
2026 (20557)
2025 (27312)
2024 (31528)
2023 (35979)
2022 (45782)
2021 (49800)
2020 (46303)
2019 (37022)
2018 (27757)
2017 (27594)
2016 (26472)
2015 (32646)
2014 (27747)
2013 (23110)
2012 (25145)
2011 (25518)
2010 (25157)
Location
Africa (649)
Alabama (95)
Alaska (7)
Arizona (374)
Arkansas (14)
Asia (34774)
Australia (5508)
California (14642)
Canada (3906)
China (1537)
Colorado (613)
Connecticut (590)
Delaware (442)
Europe (69023)
Florida (2178)
Georgia (458)
Hawaii (3)
Idaho (52)
Illinois (1075)
India (93)
Indiana (573)
Iowa (27)
Japan (623)
Kansas (127)
Kentucky (43)
Louisiana (53)
Maine (91)
Maryland (1652)
Massachusetts (10185)
Michigan (364)
Minnesota (737)
Mississippi (7)
Missouri (127)
Montana (29)
Nebraska (27)
Nevada (148)
New Hampshire (75)
New Jersey (3741)
New Mexico (26)
New York (3669)
North Carolina (1812)
North Dakota (8)
Northern California (7500)
Ohio (408)
Oklahoma (21)
Oregon (33)
Pennsylvania (2761)
Puerto Rico (33)
Rhode Island (45)
South America (888)
South Carolina (86)
South Dakota (2)
Southern California (5898)
Tennessee (185)
Texas (2383)
United States (50141)
Utah (439)
Vermont (1)
Virginia (295)
Washington D.C. (62)
Washington State (1119)
West Virginia (3)
Wisconsin (121)
Wyoming (5)
655,558 Results for "first tracks anaptysbio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
First Tracks Biotherapeutics Announces Participation in September 2026 Investor Conferences
August 26, 2026
·
1 min read
Press Releases
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
·
8 min read
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.
November 21, 2025
·
3 min read
·
Tristan Manalac
Press Releases
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
·
6 min read
Press Releases
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
March 30, 2026
·
6 min read
Press Releases
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
April 20, 2026
·
3 min read
Press Releases
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
April 20, 2026
·
3 min read
Press Releases
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
March 30, 2026
·
3 min read
Press Releases
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
July 30, 2026
·
13 min read
Mergers & acquisitions
BIO 2026: Forget dual track—biopharma deals are more complex than ever
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
June 25, 2026
·
5 min read
·
Annalee Armstrong
1 of 65,556
Next